Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.

Recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial). ClinicalTrials.gov record last updated 2026-09-04: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

Setting

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Registry

NCT06311214

Started

2025-03-18

Enrolled

Notes

ClinicalTrials.gov record last updated 2026-09-04: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

Connected

targets

TROP2

Evidence strength15/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Targets

TROP2

Sourced, not expert-reviewedEvery fact here carries a dated source and the automated checks run on every build. Next scheduled re-check 3 February 2027. No named reviewer has signed it off. It is queued for expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT06311214

A source that has moved or gone is reported by the weekly link check. /audit/

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.

Recruiting

Setting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Registry

NCT06311214

Started

2025-03-18

Enrolled

Notes

ClinicalTrials.gov record last updated 2026-09-04: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

Connected

targets

TROP2

Evidence strength15/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Targets

TROP2

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT06311214

A source that has moved or gone is reported by the weekly link check. /audit/

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Overview

Notes

Connected

targets

Sources

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Overview

Notes

Connected

targets

Sources